Back to News
Market Impact: 0.2
Bio-Thera's BAT8008 Combination Shows 61.2% Response Rate In Phase 2 Lung Cancer Study
Source: Nasdaq
Healthcare & Biotech
Bio-Thera Solutions said it presented Phase 2 results at ESMO 2026 for BAT8008 combined with BAT1308 as a first-line treatment for non-small cell lung cancer. The article provides no efficacy or safety figures, so the clinical significance cannot be assessed from the report.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results